For example, prostate specific membrane antigen or glutamate carboxypeptidase 2 (FOLH1/PSMA) was identified by sBioSITe as a cell surface protein and it is a well characterized diagnostic and potential therapeutic target in prostate cancer [43]. This evidence concerns the gene FOLH1 and prostate carcinoma.